Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.
Q2 2026 earnings reported; CagriSema Phase 3 readout timeline update
Cardiovascular outcomes data and pipeline updates across cardiometabolic franchise
Novo filed a New Jersey WARN notice for 108 employee layoffs at its Plainsboro U.S. headquarters (effective December 31, 2026) as part of a commercial sales organization redesign.
CEO Maziar Mike Doustdar disclosed at Novo's Capital Markets Day that total global workforce reductions reached 13,000 (comprising 9,000 direct restructuring layoffs and 4,000 attrition/non-backfilled departures) to reallocate capital toward next-generation metabolic R&D.
Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
Novo Nordisk said its U.S. review of a hemophilia candidate has been extended after the FDA flagged corrections needed at a manufacturing site, pushing back a potential approval decision.
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
Mylan asks US court to clear Wegovy generic from Novo patent claims
Novo Nordisk struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa's long-acting injectable drug delivery platform with its obesity and type 2 diabetes drugs.
Novo Nordisk is shortening its name to Novo as its new chief executive works to turn the Danish drugmaker around.
At its capital markets day Novo unveiled pipeline-diversification and bolt-on deal plans, but shares slid 5% as investors wanted bigger swings.
At a capital markets day in London, Novo Nordisk executives outlined a roadmap to better compete with Eli Lilly, targeting more than five multi-blockbuster launches by 2030 and more than $23 billion in annual pipeline sales by 2035.
The EU's CHMP has backed Novo's hemophilia A medicine along with seven other products.
Novo Nordisk has officially dropped the Nordisk from its corporate name as part of a broader rebranding initiative.
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
Wegovy helps free 40% of kids from obesity in phase 3 trial
Novo Nordisk's blockbuster hopes for its chronic kidney disease program dwindle after additional Phase 3 trials are scrapped.
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
China's drug regulator accepts Novo Nordisk's application for oral Wegovy
Novo Nordisk starts trialing lower maintenance doses of oral Wegovy
Novo and Amazon sign drug discovery pact, launch innovation hub
Novo Nordisk wins Netherlands GLP-1 compounding lawsuit
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Novo Nordisk makes Omnicom agency of record for US media buying
Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
Novo setback casts doubt on a new way to treat heart disease
Novo Nordisk CEO Maziar Mike Doustdar says the company is focused on building out its pipeline to move past recent clinical roadblocks.
Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week's Phase 3 failure dashed not just the Danish pharma's hopes but those of the broader inflammatio
Novo Nordisk's cardiovascular pipeline suffered a late-stage clinical failure, a setback for the company's expansion beyond diabetes and obesity.
US judge says Novo Nordisk must face lawsuit over CagriSema
A federal judge denied Novo Nordisk's motion to dismiss a securities class action lawsuit over its 2024 CagriSema obesity-pipeline readout, allowing the case to proceed.
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court. Reported by BioSpace on 2026-07-29.
Novo Nordisk is suing Eli Lilly, alleging 'misleading' advertising of obesity drugs.
Novo Nordisk sued Eli Lilly over what it calls 'deceptive' ads comparing GLP-1 drug doses.
Novo Nordisk expands in China and Czech; Cellares boosts Series D by $50M — Endpoints News coverage of biopharma industry developments.